ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the Company.
Attachment
| Source: Oculis Holding AG
ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the Company.
Attachment
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program...
Read MoreFDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program...
Read More